TUĞÇE SIRMA YUNUS İLHAN LEVENT AKMAN MUSTAFA COŞAN TEREK AHMET AYDIN ÖZSARAN NURİ YILDIRIM
Türk Jinekolojik Onkoloji Dergisi - 2023;23(2):23-32
Introduction: Pelvic exenteration is often the only curative treatment option for selected locally advanced tumors, and especially for recurrent cancers. The primary aim of this study is to assess the clinical features, types and frequency of operative and postoperative complications of patients who underwent pelvic exenteration operation by our clinic. Material and Methods: Retrospectively, between 2019 and 2023, 14 patients with primary and recurrent gynecologic tumors who underwent pelvic exenteration were assessed in our clinic. Findings: All patients treated with anterior, posterior and total exenteration. Mean age was 56 (range, 26-71 years). The most primary tumors were cervical cancer (n=5, 35.7%) and ovarian cancer (n=5, 35.7%). 28.5% of patients received neoadjuvant chemotheraphy before exenteration, 35.7% of patients were treated with primary chemo-radiotheraphy and 3 patients didn’t receive preoperative treatment. Urinary diversion was ileum conduit (64.2%). Mean operation time, estimated blood loss and hospital stay were 420 minutes, 2 units and 25 days. There were no intraoperative complications. Total morbidity rate was 28.5%; 7.1% of patients had early complications (<30 days after surgery) whereas 3 patients (21.4%) had late complications. Re-operation was not required in any patients. Disease recurrence occurred in 50% patients. There were no post-operative deaths (<30 days from surgery) nor intra-operative mortality. Eight patients died from recurrent malignancy. In our study survival was not assessed because of the short follow-up time. Results and conclusion: Pelvic exenteration is the only curative surgical method in locally invasive or recurrent gynecological tumors, with high complication rates and hospital stays.
